Table 2 Comparison of outcomes for patients with FDG-PET-positive and FDG-PET- negative recurrent papillary thyroid cancer

Disease-free survival, (months), median (range)

15 (5–33)

41 (4–67)

n.s.

Surgical treatment, (n)

7

7

n.s.

¹³¹I uptake (yes/no), n (%)

5 (23%)

8 (47%)

n.s.

¹³¹I uptake in PET-positive lesion, n =

7

¹³¹I uptake elsewhere, n =

1

¹³¹I therapy (yes/no), n (%)

10 (46%)

6 (41%)

n.s.

Outcome, n (%)

n.s.

Stable disease

5 (24%)

5 (31%)

Loco-regional control without evidence of residual disease

2 (10%)*

2 (13%)

Progressive disease

9 (43%)

9 (56%)

Death^†

5 (18%)^†

0 (0%)^†

Unknown

1